Teva Pharmaceutical Industries Ltd's market capitalization of $13,590,047,294 is ahead of 85.42% of US-listed equities.
Teva Pharmaceutical Industries Ltd's stock had its IPO on March 26, 1990, making it an older stock than 84.18% of US equities in our set.
Teva Pharmaceutical Industries Ltd's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 14.72%, greater than the shareholder yield of 87.45% of stocks in our set.
Stocks with similar financial metrics, market capitalization, and price volatility to Teva Pharmaceutical Industries Ltd are OC, IMO, ATO, CCL, and ASH.
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA) Company Bio
Teva Pharmaceuticals manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The company was founded in 1901 and is based in Petach Tikva, Israel.
TEVA Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Teva Pharmaceutical Industries Ltd with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Teva Pharmaceutical Industries Ltd ranked in the 7th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Teva Pharmaceutical Industries Ltd, consider:
Interest coverage, a measure of earnings relative to interest payments, is -4.72; that's higher than just 13.34% of US stocks in the Healthcare sector that have positive free cash flow.
The company's compound free cash flow growth rate over the past 4.74 years comes in at -0.29%; that's greater than only 5.54% of US stocks we're applying DCF forecasting to.
34% of the company's capital comes from equity, which is greater than only 10.22% of stocks in our cash flow based forecasting set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
NVST, SXTC, INFU, LUMO, and OSMT can be thought of as valuation peers to TEVA, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Databridgemarketresearch.com Present “Skeletal Complications Treatment Market– Industry Trends and Forecast to 2027” new report to its research database. The report first introduces the market basics like definitions, classifications, applications and industry chain overview, and then industry policies and plans, product
Vitiligo Treatment market report is an accurate study of the Pharmaceutical industry which gives estimations about new triumphs that will be made in the Vitiligo Treatment market in 2020-2026. It also explains what the market definition, classifications, applications, engagements, and
Coherent Market Insights released a new market study on 2018-2026 “Parkinson’s Disease Therapeutic Market” with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy-to-understand detailed analysis. At present, the market is developing its presence. The
Eating disorder market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing with the healthy CAGR in the above-mentioned research forecast period. Rising prevalence of mental
The Report Titled on “Acromegaly Market Report-Development Trends, Market Size, Industry Opportunities and Competitive Landscape in 2020” firstly introduced the Acromegaly Industry basics: The report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors.The report